Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 6/2014

Open Access 01-06-2014 | Original Article

The use of Instanyl® in the treatment of breakthrough pain in cancer patients: a 3-month observational, prospective, cohort study

Authors: Ulf E. Kongsgaard, Martin Eeg, Hanna Greisen

Published in: Supportive Care in Cancer | Issue 6/2014

Login to get access

Abstract

Purpose

Instanyl® (intranasal fentanyl spray) is a novel treatment for breakthrough pain (BTP) in cancer patients. It has shown a rapid onset of pain relief in clinical trials. This study examines the use of Instanyl® in real-life settings.

Methods

A 3-month observational, prospective, cohort study of cancer patients with BTP receiving Instanyl® (50, 100, or 200 μg) under routine clinical practice. Data were collected at three time points corresponding with routine clinic visits – baseline, Week 4, and Week 13. Primary outcomes: success of titration and maintenance dose after titration. Secondary outcomes: change in maintenance dose of Instanyl® and level of background pain medication; Brief Pain Inventory—Short Form (BPI-SF) and Patient Treatment Satisfaction Scale (PTSS) scores; adverse drug reactions (ADRs).

Results

Titration with Instanyl® was successful in 84.5 % of 309 patients; most patients were titrated at the lowest dose (50 μg). The majority showed no change in maintenance dose, with little change in the level of background pain medication. BPI-SF and PTSS scores significantly improved from baseline to Week 4. The main reason for terminating Instanyl® was death, as expected due to the underlying disease; incidence of ADRs was low and no fatal ADRs were reported.

Conclusions

In a real-life group of cancer patients with disease progression, Instanyl® was titrated successfully at doses <200 μg in the majority of patients, requiring only one dose, with no further change in maintenance dose. Pain severity, impact of pain on daily life, and treatment satisfaction significantly improved with Instanyl® treatment. No unexpected ADRs occurred.
Literature
1.
Portenoy RK, Hagen NA (1990) Breakthrough pain: definition, prevalence and characteristics. Pain 41:273–281CrossRef
2.
Haugen DF, Hjermstad MJ, Hagen N, Caraceni A, Kaasa S, European Palliative Care Research Collaborative (EPCRC) (2010) Assessment and classification of cancer breakthrough pain: a systematic literature review. Pain 149:476–482CrossRef
3.
Portenoy RK (1997) Treatment of temporal variations in chronic cancer pain. Semin Oncol 24(5 Suppl 16):S16-7-12PubMed
4.
Zeppetella G (2011) Breakthrough pain in cancer patients. Clin Oncol (R Coll Radiol) 23:393–398CrossRef
5.
Caraceni A, Bertetto O, Labianca R, for the Breakthrough/Episodic Pain Italian Study Group et al (2012) Episodic (breakthrough) pain prevalence in a population of cancer pain patients. Comparison of clinical diagnoses with the QUDEI–Italian questionnaire for intense episodic pain. J Pain Symptom Manage 43:833–841CrossRef
6.
Portenoy RK, Payne D, Jacobsen P (1999) Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 81:129–134CrossRef
7.
Davies A, Zeppetella G, Andersen S et al (2011) Multi-centre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies. Eur J Pain 15:756–763CrossRef
8.
Caraceni A, Martini C, Zecca E, Portenoy RK, for the Working Group of the IASP Task Force on Cancer Pain (2004) Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med 18:177–183CrossRef
9.
Fortner BV, Okon TA, Portenoy RK (2002) A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. J Pain 3:38–44CrossRef
10.
Abernethy AP, Wheeler JL, Fortner BV (2008) A health economic model of breakthrough pain. Am J Manag Care 14:S129–S140PubMed
11.
Fortner BV, Demarco G, Irving G, Ashley J, Keppler G, Chavez J, Munk J (2003) Description and predictors of direct and indirect costs of pain reported by cancer patients. J Pain Symptom Manage 25:9–18CrossRef
12.
Bennett D, Burton AW, Fishman S et al (2005) Consensus panel recommendations for the assessment and management of breakthrough pain: Part 2. Management. Pharm Ther 30:354–361
13.
Rustøen T, Geerling JI, Pappa T et al (2013) A European survey of oncology nurse breakthrough cancer pain practices. Eur J Oncol Nurs 17:95–100CrossRef
14.
Hagen NA, Fisher K, Victorino C, Farrar JT (2007) A titration strategy is needed to manage breakthrough cancer pain effectively: observations from data pooled from three clinical trials. J Palliat Med 10:47–55CrossRef
15.
Kleeberg UR, Filbet M, Zeppetella G (2010) Fentanyl buccal tablet for breakthrough cancer pain: why titrate? Pain Pract 11:185–190CrossRef
16.
Kress HG, Orońska A, Kaczmarek Z, Kaasa S, Colberg T, Nolte T (2009) Efficacy and tolerability of intranasal fentanyl spray 50 to 200 μg for breakthrough pain in patients with cancer: a Phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period. Clin Ther 31:1177–1191CrossRef
17.
Mercadante S, Radbruch L, Davies A et al (2009) A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial. Curr Med Res Opin 25:2805–2815CrossRef
18.
Takeda UK Ltd (2013) Instanyl® 50, 100 and 200 mcg nasal spray, solution in single-dose container. (Summary of product characteristics). Takeda UK Ltd, Buckinghamshire
19.
Mercadante S, Villari P, Casuccio A (2011) An Italian survey on the attitudes in treating breakthrough cancer pain in hospice. Support Care Cancer 19:979–983CrossRef
20.
Coluzzi PH, Schwartzberg L, Conroy JD et al (2001) Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC®) and morphine sulfate immediate release (MSIR®). Pain 91:123–130CrossRef
21.
Hanks GW, Nugent M, Higgs CM, Busch MA, OTFC Multicentre Study Group (2004) Oral transmucosal fentanyl citrate in the management of breakthrough pain in cancer: an open, multicentre, dose-titration and long-term use study. Palliat Med 18:698–704CrossRef
22.
Weinstein SM, Messina J, Xie F (2009) Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: a long-term, open-label safety study. Cancer 115:2571–2579CrossRef
23.
Foster D, Upton R, Christrup L, Popper L (2008) Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery. Ann Pharmacother 42:1380–1387CrossRef
24.
Portenoy RK, Payne R, Coluzzi P et al (1999) Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain 79:303–312CrossRef
25.
Verheggen FW, Nieman FH, Reerink E, Kok GJ (1998) Patient satisfaction with clinical trial participation. Int J Qual Health Care 10:319–330CrossRef
Metadata
Title
The use of Instanyl® in the treatment of breakthrough pain in cancer patients: a 3-month observational, prospective, cohort study
Authors
Ulf E. Kongsgaard
Martin Eeg
Hanna Greisen
Publication date
01-06-2014
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 6/2014
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-014-2128-0

Other articles of this Issue 6/2014

Supportive Care in Cancer 6/2014 Go to the issue

Original Article

Incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant

Original Article

Quality of life in long-term survivors following treatment for Hodgkin's disease during childhood and adolescence in the German multicentre studies between 1978 and 2002

Original Article

Comparison of timing and decision-makers of do-not-resuscitate orders between thoracic cancer and non-cancer respiratory disease patients dying in a Japanese acute care hospital

Original Article

Awareness, concern, and communication between physicians and patients on bone health in cancer

Original Article

Complementary and alternative medicine use and disclosure amongst Australian radiotherapy patients

Original Article

Factors related to clinically relevant fatigue in disease-free stomach cancer survivors and expectation–outcome consistency
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits